Browsing by Author "Faunes, Miriam"
Now showing 1 - 4 of 4
Results Per Page
Sort Options
- ItemChylothorax in congenital diaphragmatic hernia(2010) Zavala, Alejandro; Campos, Jose-Manuel; Riutort, Cecilia; Skorin, Ilona; Godoy, Loreto; Faunes, Miriam; Kattan, JavierFollowing surgical repair of congenital diaphragmatic hernia (CDH), chylothorax can be present in 7-28% of the cases. It has been associated with prenatal diagnosis, the use of ECMO and prosthetic patches during reparatory surgery. The objective is to present a neonatal unit experience in handling this complication and the search for predictive factors for its appearance in our patients.
- ItemGrowth of Very Low Birth Weight Infants Who Received a Liquid Human Milk Fortifier: A Randomized, Controlled Multicenter Trial(2022) Masoli, Daniela; Mena, Patricia; Domínguez, Angélica; Ramolfo, Pamela; Vernal, Patricia; Pantoja, Miguel Angel; Esparza, Ruth; Hübner, Maria Eugenia; Ríos, Antonio; Faunes, Miriam; Uauy, Ricardo; Tapia, Jose L.; Neocosur NetworkObjectives: To evaluate growth (weight, length, head circumference, and knee–heel length [KHL]) in very low birth weight (VLBW) infants (500–1500 g) who received human milk with a liquid fortifier (LHMF) with high protein and fatty acid content versus a traditional powder fortifier (PHMF) for 45 days or until discharge. Methods: This was a multicenter, randomized, controlled trial. An intention-to-treat analysis was performed to determine adverse events and withdrawal causes. We also performed an efficacy analysis involving the infants who completed at least 2 weeks of study. Results: Of the 158 infants enrolled in the study, 146 completed at least 2 weeks, and 125 completed the entire study. The biodemographic characteristics were similar between groups, with no differences in increments of weight (22.9 vs 22.7 g kg−1 day−1), length (1.03 vs 1.09 cm/week), head circumference (0.91 vs 0.90 cm/week), or KHL (3.6 vs 3.3 mm/week). The KHL increment was greater in infants weighing >1 kg receiving LHMF (3.7 vs 3.2 mm/week, P = 0.027). Although there were no significant differences in serious adverse events, the incidence difference of the composite outcome death/necrotizing enterocolitis between groups warrants attention (1.3% with LHMF and 8.1% with PHMF). Conclusion: There were no differences in the overall growth between VLBW infants receiving either fortifier.
- ItemImprovement of survival in infants with congenital diaphragmatic hernia in recent years: effect of ECMO availability and associated factors(2010) Kattan, Javier; Godoy, Loreto; Zavala, Alejandro; Faunes, Miriam; Becker, Pedro; Estay, Alberto; Fabres, Jorge; Toso, Paulina; Urzua, Soledad; Becker, Jorge; Cerda, Jaime; Gonzalez, AlvaroSurvival of patients with congenital diaphragmatic hernia (CDH) depends both on non-modifiable congenital conditions and on modifiable pre and postnatal management. ECMO improves survival up to 80% in neonates with CDH in the best ECMO centers worldwide. The first Neonatal ECMO Program in Chile was started in our University in 2003. Our objective is to determine the impact of a Neonatal ECMO Program in a level III NICU on newborns with CDH.
- ItemOxigenación con membrana extracorpórea en pacientes pediátricos. Comunicación de los 3 primeros casos tratados(2005) Kattan, Javier; González, Álvaro; Becker, Pedro; Rodríguez, José; Estay, Alberto; Faunes, Miriam; Fajardo, Christian; Canessa, RobertoExtracorporeal membrane oxygenation (ECMO) improves survival in neonatal and pediatric patients with reversible severe respiratory or cardiac failure, in whom intensive treatment fails. Since 1999, a multidisciplinary team is trained to form the first neonatal-pediatric ECMO center in Chile, according to the norms of the Extracorporeal Life Support Organization (ELSO). During 2003 the first three patients were admitted to the program: a male newborn with pulmonary hypertension, a 38 days old female operated for a total anomalous pulmonary venous connection and a 3 months old male with a severe pneumonia caused by respiratory syncytial virus. They remained in ECMO for five, seven and nine days respectively and all survived to the procedure. No neurological complications were observed after one and a half year of follow up. This consolidates the first national neonatal-pediatric ECMO program, associated to ELSO. Up to date, twelve patients have been admitted to the program (Rev Méd Chile 2005; 133: 1065-70).